Furthermore, the demonstration of cardiovascular benefits across a broad range of adiposity levels, coupled with independence from weight loss magnitude, suggests that semaglutide and perhaps other GLP-1 receptor agonists should be reconceptualized as cardiovascular disease-modifying agents rather than solely medications for glycemic control or weight loss
Never throw needles in regular trash
Since the unavailability of crystal structures of OATPs and relative difficulties in validating their homology models, pharmacophore models have helped elucidate the key molecular features involved in the substrate/inhibitor and protein interactions
Embracing Uncertainty, Elevating Insight
20 demonstrated, while some patients may require long-term therapy at the full dose for weight maintenance, others can taper their dose to a reduced maintenance level, and some may be able to discontinue therapy entirely whilst maintaining their desired weight